Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 4 1

Status

Terminated 2Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5Gynecologic 1

Conditions

Breast Neoplasms 243Neoplasms 17Neoplasm Metastasis 15Carcinoma, Intraductal, Noninfiltrating 11Breast Diseases 8Advanced Breast Cancer 8Breast Neoplasms, Male 7Breast Carcinoma In Situ 7Triple Negative Breast Neoplasms 5Ovarian Neoplasms 5Endometrial Neoplasms 5Arthralgia 5Neoplasms by Site 3Breast Cancer Metastatic 3Uterine Cervical Neoplasms 2Recurrence 2Patient Compliance 2Osteoporosis 2Obesity 2Multiple Endocrine Neoplasia Type 1 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasm Female 2Vitamin D Deficiency 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Skin Diseases 1Sexual Dysfunctions, Psychological 1Sexual Dysfunction, Physiological 1Seizures 1Sarcoma 1

Interventions

pembrolizumab 163Carboplatin 146Paclitaxel 125Cyclophosphamide 94130-nm albumin-bound paclitaxel 66Capecitabine 64Gemcitabine 54Doxorubicin 50Albumin-Bound Paclitaxel 45Taxes 42atezolizumab 41Cisplatin 39sacituzumab govitecan 34Nivolumab 34olaparib 32Epirubicin 32Specimen Handling 28Docetaxel 28eribulin 27Bevacizumab 26durvalumab 25Drug Therapy 25Biopsy 24camrelizumab 23Magnetic Resonance Spectroscopy 22toripalimab 19Radiotherapy 17spartalizumab 16Everolimus 15veliparib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Anastrozole × Clear all
NCT04556773 2025-12-17

DB-08

AstraZeneca

Phase 1 Active not recruiting
138 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02648477 2024-03-19

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

City of Hope Medical Center

Phase 2 Completed
30 enrolled 11 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01234532 2022-05-03

0927GCC

University of Maryland, Baltimore

Phase 2 Terminated
5 enrolled 7 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02476955 2020-09-30

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Terminated
41 enrolled
BreastGynecologic

Uterine Cervical Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02089854 2016-12-02

AETNBC

Peking Union Medical College Hospital

Phase 4 Unknown
800 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡